克罗恩病治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00004296
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

[研究报告]2023年克罗恩病治疗市场价值为96.8亿美元,预计到2031年将达到133.3亿美元。预计2023-2031年复合年增长率为4.1%。

市场洞察和分析师观点:

克罗恩病是一种主要影响胃肠道的慢性炎症性疾病。它通常影响小肠的末端和大肠的起始部分。该疾病的特点是消化道内壁炎症,导致腹痛、腹泻和营养不良等症状。克罗恩病治疗市场规模的不断增长归因于西方国家(尤其是美国)疾病患病率的不断上升。此外,公司为保持市场竞争力而采取的战略举措也正在推动市场增长。先进医疗设备使用的显着增加可能会在预测期内带来新的克罗恩病治疗市场趋势。

增长动力和挑战:

克罗恩病是一种肠易激综合症,一种慢性炎症性肠病,没有特效治疗方法。这种疾病的确切病因尚不清楚,但这种疾病主要是肠道对药物、毒素、感染和肠道微生物以及其他环境因素的不适当免疫反应的结果,特别是在遗传易感宿主中。据美国国家医学图书馆介绍,克罗恩病(CD)在西方发达国家更为常见,尤其是北美和北欧国家以及新西兰。该病好发于15~30岁和40~60岁人群,以城市地区更为突出。该病在北欧国家和犹太裔人群中发病率较高,为3.2/1,000。然而,最近的研究表明,由于亚洲、非洲和澳大利亚的快速工业化,该地区的发病率也显着增加。因此,克罗恩病在各自地区的惊人患病率推动了克罗恩病治疗市场的发展。

根据美国国立卫生研究院的数据,克罗恩病造成了巨大的经济负担,每位患者的直接医疗费用约为 3,500 美元欧洲每年。每 10 万人中大约有 322 人受到这种疾病的影响。然而,不同国家的患病率可能有所不同。超过50%的克罗恩病患者可能没有被正式诊断,或者可能表现出与其他消化道疾病相同的症状。与男性相比,克罗恩病在女性中更为常见,也就是说,其影响的女性可能是男性的三倍。

参与肠易激综合症药物开发的公司正在采取建设性措施来实施意识计划,以期实现这一目标通过传播对症状、诊断和治疗的认识来有效应对这种综合症。 2018 年,艾尔建 (Allergan PLC) 和 Ironwood 合作推出了交互式数字目的地平台,鼓励患者接受教育并采取行动对抗消化道疾病。因此,肠易激综合症患病率的上升推动了克罗恩病治疗市场的增长。

战略见解

报告细分和范围:

克罗恩病治疗市场分析已通过考虑以下部分来进行:药物类型、分销渠道和地理位置。按药物类别划分,市场分为抗炎药、免疫系统抑制剂、抗生素、生物制剂、止泻药和止痛药。生物制品细分市场在2023年占据最大市场份额。抗炎药细分市场预计在2023年至2031年期间将创下最高复合年增长率。

根据最终用户,市场分为医院药房、临床药房,以及在线其他人。 2023年,医院药房领域占据了最大的克罗恩病治疗市场份额。从地域来看,克罗恩病治疗市场报告的范围包括北美(美国、加拿大和墨西哥)、欧洲(西班牙、英国、德国、法国、意大利和欧洲其他地区)、亚太地区(韩国、中国、日本、印度、澳大利亚和亚太地区其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋和中东和其他地区)非洲)以及南美洲和中美洲(巴西、阿根廷以及南美洲和中美洲其他地区)。

区域分析:

北美是全球克罗恩病治疗市场的最大贡献者生长。预计 2023 年至 2031 年,亚太地区将创下市场最高复合年增长率。北美市场的进步归因于慢性病发病率的上升、技术的进步和技术先进的医疗产品的获取、老年人口的激增以及参与新产品和现有产品开发的主要市场参与者的存在。 2023 年,美国将占据北美最大的克罗恩病治疗市场份额。

克罗恩病治疗市场(按分销渠道划分)——2023 年和 2031 年

行业发展和未来机遇:
< br>克罗恩病治疗市场预测是根据各种二级和一级研究结果估计的,例如主要公司出版物、协会数据和数据库。根据公司新闻稿,克罗恩病治疗市场主要参与者的主要进展如下:

2023 年,美国食品和药物管理局 (FDA) 批准了第一种口服药丸 — Rinvoq(upadacitinib)——治疗中度至重度克罗恩病。 Rinvoq 旨在治疗无法用阻断肿瘤坏死因子 (TNF) 的候选药物成功治疗的成年患者。2022 年,FDA 批准 Skyrizi 用于治疗中度至重度活动性克罗恩病成人患者。 2021年,艾伯维公司宣布启动risankizumab治疗克罗恩病的3期试验。 Risankizumab 是一种人源化单克隆抗体,选择性靶向白细胞介素 23 (IL-23) 通路。该试验旨在评估 risankizumab 对中重度克罗恩病患者的疗效和安全性。 2021 年,武田药品工业株式会社宣布启动口服化合物 TAK-721 的 3 期试验。克罗恩病的治疗。 TAK-721 是趋化因子受体 CXCR3 的选择性拮抗剂。该试验旨在评估 TAK-721 对中重度克罗恩病患者的疗效和安全性。竞争格局和主要公司:

Abbvie, Inc.;强生私人有限公司;葛兰素史克公司;默克公司;诺华公司;新基公司;基因泰克;辉瑞公司;雀巢健康科学;和勃林格殷格翰有限公司是克罗恩病治疗市场报告中介绍的知名参与者之一。此外,研究期间还对其他几家参与者进行了研究和分析,以全面了解市场及其生态系统。这些公司专注于地域扩张和新产品发布,以满足全球消费者不断增长的需求,并通过专业产品组合扩大其产品范围。他们的全球业务使他们能够为庞大的客户群提供服务,从而促进市场扩张。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which segment is dominating the Crohn’s Disease Therapeutics Market?

The Crohn’s disease therapeutics market, based on drug class, is segmented into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal, and pain reliever. In 2023, the biologics segment held the largest Crohn’s disease therapeutics market share. The Crohn’s disease therapeutics market, by distribution channel, is segmented into hospital pharmacy, retail pharmacy, online pharmacy. In 2023, the hospital pharmacy segment held the largest Crohn’s disease therapeutics market share and is anticipated to record the highest CAGR during 2023–2031.

Who are the major players in market the Crohn’s Disease Therapeutics Market?

The Crohn’s Disease Therapeutics Market majorly consists of the players such Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim Gmbh

What is Crohn’s disease therapeutics Market?

Crohn's disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract. It commonly affects the end part of the small intestine and the beginning of the large intestine. The disease is characterized by the inflammation of the digestive tract lining, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. The growing Crohn's disease therapeutics market size is attributed to the increasing prevalence of diseases in Western countries, particularly the US. In addition, strategic initiatives by companies to stay competitive in the market are fueling market growth. A significant increase in the use of medical devices is likely to bring new Crohn's disease therapeutics market trends during the forecast period.

Which region is dominating the Crohn’s Disease Therapeutics Market?

Based on geography, the Crohn’s Disease Therapeutics Market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to the growth of the global Crohn’s Disease Therapeutics Market. Asia Pacific is expected to register the highest CAGR in the Crohn’s Disease Therapeutics Market during 2023–2031.

What is the driving and restraining factors for the Crohn’s Disease Therapeutics Market?

The increasing burden of irritable bowel syndrome, and the increasing in number of FDA approval and drug development bolster the Crohn’s disease therapeutics market size. However, the high cost of the treatment hinders the Crohn’s disease therapeutics market growth.

The List of Companies - Crohn's Disease Therapeutics Market

  1. ABBVIE, INC.
  2. JOHNSON AND JOHNSON PRIVATE LIMITED
  3. GLAXOSMITHKLINE PLC
  4. MERCK AND CO., INC.
  5. NOVARTIS AG
  6. CELGENE CORPORATION
  7. GENENTECH
  8. PFIZER INC.
  9. NESTLe HEALTH SCIENCE
  10. BOEHRINGER INGELHEIM GMBH

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports